Protein Kinases and Protein Phosphatases in Signal Transduction Pathways

作者: T.K. Sawyer

DOI: 10.1016/B0-08-045044-X/00070-5

关键词:

摘要: Protein phosphorylation has become a central focus of drug discovery as the result identification and validation promising therapeutic targets such protein kinases, phosphatases, phosphoprotein binding domains.1–24 With respect to targets, significant progress been made in mapping signal transduction pathways involved disease, including particular molecular genesis and/or sustainment various cancers, several inflammatory, immune, metabolic, bone diseases. is an extraordinarily important component life processes, underlying cellular proliferation, differentiation, metabolism, survival, motility, gene transcription. complex phenomenon, with triggering, compensatory mechanisms, both spatial temporal factors contributing biological specificity functional endpoints within milieu. The global state proteins cells fundamentally impossible decipher at high resolution, even though sophisticated methods (e.g., mass spectrometry, interaction traps, affinity chromatography) are emerging that can be used analyze so-called phosphoproteome. In this chapter, described relative our current understanding biology kinase, phosphatase, phosphoprotein-interacting domain containing intracellular proteins. addition few noteworthy examples focused on developing small-molecule inhibitors described.

参考文章(282)
Jacqueline S. Biscardi, David A. Tice, Sarah J. Parsons, c-Src, Receptor Tyrosine Kinases, and Human Cancer Advances in Cancer Research. ,vol. 76, pp. 61- 119 ,(1999) , 10.1016/S0065-230X(08)60774-5
Gerhard Müller, Peptidomimetic SH2 Domain Antagonists for Targeting Signal Transduction Springer, Berlin, Heidelberg. pp. 17- 59 ,(2000) , 10.1007/3-540-45035-1_2
Peter Campochiaro, Stephan Bodis, Doriano Fabbro, Terence O'Reilly, Martin Pruschy, Jeanette Wood, Stephan Ruetz, Thomas Meyer, Katalin Csermak, Anthony Man, PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anti-cancer Drug Design. ,vol. 15, pp. 17- 28 ,(2000)
Christopher J. Torrance, Peta E. Jackson, Elizabeth Montgomery, Kenneth W. Kinzler, Bert Vogelstein, Allan Wissner, Maria Nunes, Philip Frost, Carolyn M. Discafani, Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine. ,vol. 6, pp. 1024- 1028 ,(2000) , 10.1038/79534
Bayard Clarkson, Christian Peschel, W Todd Miller, Jana Sänger, Wanqing Li, William G Bornmann, Darren R Veach, Justus Duyster, Nikolas von Bubnoff, Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors Cancer Research. ,vol. 63, pp. 6395- 6404 ,(2003)
Judith S. Sebolt-Leopold, David T. Dudley, Roman Herrera, Keri Van Becelaere, Amy Wiland, Richard C. Gowan, Haile Tecle, Stephen D. Barrett, Alexander Bridges, Sally Przybranowski, W.R. Leopold, Alan R. Saltiel, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine. ,vol. 5, pp. 810- 816 ,(1999) , 10.1038/10533
Adrian M. Senderowicz, Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investigational New Drugs. ,vol. 17, pp. 313- 320 ,(1999) , 10.1023/A:1006353008903
John C.H. Byon, Anasua B. Kusari, Jyotirmoy Kusari, Protein-tyrosine Phosphatase-1B acts as a negative regulator of insulin signal transduction Insulin Action. ,vol. 182, pp. 101- 108 ,(1998) , 10.1007/978-1-4615-5647-3_11
N K Tonks, C D Diltz, E H Fischer, Purification of the major protein-tyrosine-phosphatases of human placenta. Journal of Biological Chemistry. ,vol. 263, pp. 6722- 6730 ,(1988) , 10.1016/S0021-9258(18)68702-2
Gerard I. Evan, Karen H. Vousden, Proliferation, cell cycle and apoptosis in cancer Nature. ,vol. 411, pp. 342- 348 ,(2001) , 10.1038/35077213